Lacosamide API specifications: reading the impurity profile

What the analytical data package should contain before you commit to a supplier.

Lacosamide is a single-enantiomer molecule, and that one fact reorganises the whole conversation with a supplier. Price and assay tell you less than the chiral and impurity data, and those are the numbers that are easiest to gloss over on a first-pass specification sheet.

What Lacosamide is used for

Lacosamide is an anti-epileptic formulated for partial-onset seizures, usually as a monotherapy or adjunct, and is available in oral solid and, in some markets, intravenous forms. For a formulator, that means the same API may feed both a tablet and an injectable dossier, each with its own release requirements.

The clinical position of the molecule is stable enough that most demand is generic. The differentiation you are buying, then, is not the indication but the consistency of the material and the completeness of the evidence that comes with it.

Enantiomeric purity is the first line to read

Because Lacosamide is the R-enantiomer, the presence of its S-counterpart is a specific impurity, not a general one. Ask for the chiral purity method and the limit the supplier releases against, and confirm it is stated as an enantiomeric ratio, not folded into a single total-impurity figure.

A specification that reports assay and total impurities but is quiet on chiral purity is incomplete for this molecule. The chiral column, the reference standard used and the reported enantiomeric excess belong on the sheet you evaluate, not in a follow-up email after the PO.

Grade and monograph differences that change a filing

Monograph coverage for Lacosamide varies by pharmacopoeia, and where a compendial monograph does not yet apply in your target market you will be releasing against an in-house specification. Ask which monograph, or which in-house method, the quoted material is controlled to, because the two are not interchangeable in a dossier.

The analytical methods that demonstrate those limits differ as well. A price quoted against an in-house specification is not comparable to one quoted against a compendial grade, and confusing the two is a common reason two quotations look further apart than they are.

Impurity profile and route consistency

Impurities follow the synthetic route, so a supplier who changes route between campaigns hands you a fresh profile to justify. For a single-enantiomer drug that is doubly true, because the route also governs how cleanly the wanted enantiomer is separated.

For a single-enantiomer API, a specification sheet that omits the chiral purity method is not a specification you can file against.

The question worth asking is not only “what is your impurity profile” but “has your route changed in the last three years, and does your chiral separation method carry a validated limit for the opposite enantiomer”.

Documentation to request before the first PO

A batch Certificate of Analysis, the method of analysis, the chiral purity method, an MSDS and the product specification should be available before you order. DMF and open-part documentation should be available on request where your filing requires it.

How completely and how quickly a supplier sends that set is an early signal you can trust. A supplier who has the chiral data ready at enquiry stage is telling you they release against it routinely, which is exactly what you want to know before the material is in your warehouse.

A short checklist before you commit

• Confirm the chiral purity method and the enantiomeric-excess limit in writing.
• Ask which monograph or in-house specification the price is quoted against.
• Request a batch CoA and full method of analysis before raising the PO.
• Confirm whether the synthetic route has changed recently.
• Establish who prepares export documentation, and how long it takes.